To meet these needs, we and others designed non-attenuated o-HSVs retargeted to cancer specific receptors of choice, exemplified by IL13Rα2 (Interleukin 13 receptor α2), HER2 (human epidermal growth factor receptor 2), EGFR (epidermal growth factor receptor), and uPAR (urokinase plasminogen activator receptor) [23,24,25,26,27,28,29]. This evidence concerns the gene PLAUR and cancer.